Novel hybrids from N-hydroxyarylamide and indole ring through click chemistry as histone deacetylase inhibitors with potent antitumor activities

Chinese Chemical Letters

Volumn 26, Issue 6, 2015, Pages 675-680

  Cai, Mao ^a   Hu, Jie ^b   Tian, Ji Lai ^c   Yan, Huang ^a   Zheng, Chen Guo ^a   Hu, Wan Le ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c Southeast University   (China)

Author keywords

Anti tumor agents; Click chemistry; Histone deacetylase inhibitors; N Hydroxyarylamides; Synthesis

Indexed keywords

EID: 84927914516     PISSN: 10018417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cclet.2015.03.015     Document Type: Article

References (27)

1. Z. Li, and W.G. Zhu Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications Int. J. Biol. Sci. 10 2014 757 770
2. C.B. Yoo, and P.A. Jones Epigenetic therapy of cancer: past, present and future Nat. Rev. Drug Discov. 5 2006 37 50
3. L. Simó-Riudalbas, and M. Esteller Targeting the histone orthography of cancer: drugs for writers, erasers and readers, Br J. Pharmacol. 172 2015 2716 2732
4. H. Lehrmann, L.L. Pritchard, A. Harel-Bellan, and et al. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation Adv. Cancer Res. 86 2002 41 65
5. B.E. Bernstein, J.K. Tong, and S.L. Schreiber Genome wide studies of histone deacetylase function in yeast Proc. Natl. Acad. Sci. U. S. A. 97 2000 13708 13713
6. O. Witt, H.E. Deubzer, T. Milde, I. Oehme, and et al. HDAC family: what are the cancer relevant targets Cancer Lett. 277 2009 8 21
7. P. Bose, Y. Dai, and S. Grant Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights Pharmacol. Ther. 143 2014 323 336
8. A.C. West, and R.W. Johnstone New and emerging HDAC inhibitors for cancer treatment J. Clin. Invest. 124 2014 30 39
9. M. Slingerland, H.J. Guchelaar, and H. Gelderblom Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors Anticancer Drugs 25 2014 140 149
10. P.A. Marks Discovery and development of SAHA as an anticancer agent Oncogene 26 2007 1351 1356
11. FK228: http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/2009/ucm189629.htm.
12. T. Qiu, L. Zhou, W. Zhu, and et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials Future Oncol. 9 2013 255 269
13. T. You, K. Chen, F.H. Wang, and et al. Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors Chin. Chem. Lett. 25 2014 474 478
14. T.A. Miller, D.J. Witter, and S. Belvedere Histone deacetylase inhibitors J. Med. Chem. 46 2003 5097 5116
15. P.A. Marks The clinical development of histone deacetylase inhibitors as targeted anticancer drugs Expert Opin. Invest. Drugs 19 2010 1049 1066
16. J. McDermott, and A. Jimeno Belinostat for the treatment of peripheral T-cell lymphomas Drugs Today (Barc.) 50 2014 337 345
17. W.P. Yong, B.C. Goh, R.A. Soo, and et al. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies Ann. Oncol. 22 2011 2516 2522
18. J.S. de Bono, R. Kristeleit, A. Tolcher, and et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors Clin. Cancer Res. 14 2008 6663 6673
19. S. Fouliard, R. Robert, A. Jacquet-Bescond, and et al. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I Eur. J. Cancer 49 2013 2791 2797
20. A. Furlan, V. Monzani, L.L. Reznikov, and et al. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat) Mol. Med. 17 2011 353 362
21. Ø. Bruserud, C. Stapnes, E. Ersvaer, and et al. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell Curr. Pharm. Biotechnol. 8 2007 388 400
22. J. Amato, N. Iaccarino, B. Pagano, and et al. Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex Front. Chem. 2 2014 54
23. M.T. Macdonough, T.E. Strecker, E. Hamel, and et al. Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3′-hydroxy-4′-methoxyphenyl)-3-(3″,4Prime;,5Prime;-trimethoxybenzoyl)-6-methoxyindole (OXi8006) Bioorg. Med. Chem. 21 2013 6831 6843
24. Y.S. Cho, L. Whitehead, J. Li, and et al. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824) J. Med. Chem. 53 2010 2952 2963
25. C.D. Hein, X.M. Liu, and D. Wang Click chemistry, a powerful tool for pharmaceutical sciences Pharm. Res. 25 2008 2216 2230
26. G.C. Tron, T. Pirali, R.A. Billington, and et al. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes Med. Res. Rev. 28 2008 278 308
27. A.R. Bogdan, and K. James Efficient access to new chemical space through flow-construction of druglike macrocycles through copper-surface-catalyzed azide-alkyne cycloaddition reactions Chemistry 16 2010 14506 14512